DRUG
Intranasal Oxytocin (IN-OXT)
Subject assigned to receive intranasal administration of oxytocin (24 IU).
The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling
Status
Completed
Phase
Not applicable
Enrollment
120
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.
Full detailed description
A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.
Interventions
Treatment arms and agents.
DRUG
Intranasal Vasopressin (AVP)
Subjects assigned to receive intranasal administration of vasopressin (20 IU).
DRUG
Intranasal Placebo
Subjects assigned to receive intranasal administration of placebo.
Timeline
From registration to results.
First posted
Sep 20, 2024
Study start
Oct 2, 2024
Primary completion
Jul 28, 2025
Study completion
Aug 12, 2025
Results posted
Not reported
Registry updated
Oct 3, 2025
Outcomes
What the study measures.
Primary outcomes
Resting-state EEG
Time frame · 35-50 minutes after treatment administration.
Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index.
Behavioral indices in the tasks
Time frame · 50-90 minutes after treatment administration.
Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious).
Task-based EEG
Time frame · 50-90 minutes after treatment administration.
EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses.
Secondary outcomes
SCR in anxiety induction
Time frame · 70-90 minutes after treatment administration.
Skin Conductance Response (SCR) data are recorded in the anxiety induction task under safe and anxious conditions.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 30 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Healthy subjects without past or current psychiatric or neurological disorders. Exclusion Criteria: * History of head injury. * Pregnant,menstruating,taking oral contraceptives. * Medical or psychiatric illness.
Study locations
2 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
University of Electronic Science and Technology of China
Chengdu, Chengdu, China
University of Electronic Science and Technology of China (UESTC)
Chengdu, Sichuan, China
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Vasopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Mifepristone vs Misoprostol
Montefiore Medical Center · Cervical Preparation
Phase 1
Recruiting
94
2026-07
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremias · Water Intoxication
Phase 3
Completed
205
2026-07
Study of Ascending Levels of Tolvaptan in Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremia
Phase 3
Completed
243
2026-07
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.